학술논문
FANSY POSTCOV: A composite clinical immunological predictive index for post‐COVID‐19 syndrome unveils distinctive features in a cohort study of mild to critical patients.
Document Type
Article
Author
Torres‐Ruiz, Jiram; Lomelín‐Gascón, Julieta; Lira‐Luna, Jaquelin; Pérez‐Fragoso, Alfredo; Tapia‐Conyer, Roberto; Nuñez‐Aguirre, Miroslava; Alcalá‐Carmona, Beatriz; Absalón‐Aguilar, Abdiel; Maravillas‐Montero, José Luis; Mejía‐Domínguez, Nancy Raquel; Núñez‐Álvarez, Carlos; Llorente, Luis; Romero‐Ramírez, Sandra; Sosa‐Hernández, Victor Andrés; Cervantes‐Díaz, Rodrigo; Juárez‐Vega, Guillermo; Meza‐Sánchez, David; Rull‐Gabayet, Marina; Martínez‐Juárez, Luis Alberto; Morales‐Juárez, Linda
Source
Subject
*COVID-19 pandemic
*COVID-19
*GRANULOCYTES
*IMMUNOLOGIC memory
*HELLP syndrome
*MEDICAL personnel
*POST-acute COVID-19 syndrome
*
*
*
*
*
*
Language
ISSN
2001-1326
Abstract
Dear Editor, The post-coronavirus disease 2019 (COVID-19) syndrome encompasses the persistence of symptoms for more than 12 weeks after infection onset.1 It causes multiorgan damage and disability, has an unclear pathogenesis and lacks biomarkers.1 Our study provides evidence of the clinical and immunological signatures of post-COVID-19 syndrome to identify at-risk patients who may benefit from therapy in a timely manner. Patients with the post-COVID-19 syndrome had higher serum levels of anti-SARS-CoV2 IgG antibodies ( I p i = .01), granulocyte-macrophage colony-stimulating factor (GM-CSF; I p i = .02) and vascular endothelial growth factor (VEGF; I p i = .009). FANSY POSTCOV: A composite clinical immunological predictive index for post-COVID-19 syndrome unveils distinctive features in a cohort study of mild to critical patients. [Extracted from the article]